Dileepan, Thamotharampillai http://orcid.org/0000-0002-2810-6996
Malhotra, Deepali http://orcid.org/0000-0002-8215-7639
Kotov, Dmitri I. http://orcid.org/0000-0001-7843-1503
Kolawole, Elizabeth M. http://orcid.org/0000-0003-3138-0037
Krueger, Peter D.
Evavold, Brian D.
Jenkins, Marc K. http://orcid.org/0000-0001-8009-7655
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (T32 AI083196, T32 AI007313, R01 AI096879, R01 AI143826, R01 AI039614)
Article History
Received: 6 September 2019
Accepted: 12 March 2021
First Online: 3 May 2021
Ethics
: Experiments were approved by the University of Minnesota Institutional Animal Care and Use Committee and conducted in accordance with its policies.
: M.K.J, T.D. and D.M. are co-inventors on a patent application covering CD4 affinity enhanced p:MHCII tetramers owned by Regents of the University of Minnesota (#PCT/US19/44605 – Co-receptor affinity enhanced major histocompatibility class II molecules).